Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine

Pain Physician

Volumn 15, Issue 5, 2012, Pages

  Pesce, Amadeo ^a   West, Cameron ^a   Gonzales, Elizabeth ^a   Rosenthal, Murray ^a   West, Robert ^a   Mikel, Charles ^a   Almazan, Perla ^a   Latyshev, Sergey ^a   Horn, Paul ^b  

^a Millenium Research Institute   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Hydrocodone; Illicit drug use; Morphine; Oxycodone; Patients with pain

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE; DIAMORPHINE; HYDROCODONE; ILLICIT DRUG; METHAMPHETAMINE; MORPHINE; OXYCODONE; PHENCYCLIDINE;

ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; DRUG DETERMINATION; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; URINALYSIS;

ANALGESICS, OPIOID; HUMANS; HYDROCODONE; MORPHINE; OXYCODONE; PAIN; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE ABUSE DETECTION;

EID: 84866979351     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, and Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003; 97:1097-1102.
2. Manchikanti L, Damron K, McManus CD, and Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study. Pain Physician 2004; 7:431-437.
3. Manchikanti L, Manchukonda R, Pampati V, and Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving shortacting (hydrocodone) or long-acting (methadone) opioids. Pain Physician 2005; 8:257-261.
4. Manchikanti L, Manchukonda R, Pampati V, Damron K, Brandon D, Cash KA, and McManus CD. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006; 9:123-129.
5. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, and McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician 2006; 9:215-226.
6. Michna E, Jamison RN, Pham LD, Ross EL, Janfaza D, Nedeljkovic SS, Narang S, Palombi D, and Wasan AD. Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain 2007; 23:173-179.
7. Cone EJ, Caplan YH, Black DL, Robert T, and Moser F. Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol 2008; 32:530-543.
8. Pesce A, West C, Rosenthal M, Mikel C, West R, Crews B, Almazan P, Latyshev S, and Horn P. Illicit drug use in the pain patient population decreases with more frequent drug testing. Pain Physician 2011; 14:189-193.
9. Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latyshev S, and Horn P. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician 2010; 13:283-287.
10. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, Jasper JF, Singh V, Jordan AE, Johnson BW, Cicala RS, Dunbar EE, Helm S, II, Varley KG, Suchdev PK, Swicegood JR, Calodney AK, Ogoke BA, Minore WS, and Manchikanti L. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 9:1-40.
11. Reisfield GM, Salazar E, and Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007; 37:301-314.
12. Hammett-Stabler CA, and Webster LR. A clinical guide to urine drug testing: Augmenting pain management and enhancing patient care. University of Medicine and Dentistry of New Jersay Center for Continuing and Outreach Education. Stamford, CT: PharmaCom Group, Inc, 2008.
13. Nafziger AN, and Bertino JS, Jr. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain 2009; 25:73-79.
14. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, and Miaskowski C. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
15. Gourlay DL, Heit HA, and Caplan YH. Urine drug testing in clinical practice: The art and science of patient care. California Academy of Family Physicians. Stamford, CT: PharmaCom Group, Inc., 2010.
16. Model Policy for the Use of Controlled Substances for the Treatment of Pain. House of Delegates of the Federation of State Medical Boards of the United States, Inc., 2004. Accessed May 25, 2010 from www.fsmb.org/pdf/2004_grpol_controlled_substances.pdf
17. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, and Portenoy RK. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:131-146.
18. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser S, Adlaka R, Patel S, and Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician 2008; 11:S5-S62.
19. Pesce A, Rosenthal M, West R, West C, Crews B, Mikel C, Almazan P, and Latyshev S. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010; 13:273-281.
20. Regårdh CG. Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion. J Clin Hosp Pharm 1985; 10:337-349.
21. "Introduction to Pharmacokinetics." (2008). Redwood City, CA: RMI Pharmacokinetics. Retrieved May 23, 2012 from .
22. West R, Pesce A, West C, Crews B, Mikel C, Almazan P, Rosenthal M, and Latyshev S. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LCMS/MS in pain management population. Pain Physician 2010; 13:71-78.
23. Pesce A, West C, West R, Crews B, Mikel C, Rosenthal M, Almazan P, and Latyshev S. Determination of medication cutoff values in a pain patient population. J Opioid Manag 2011; 7(2):117-122.
24. West R, Pesce A, Crews B, Mikel C, Rosenthal M, Almazan P, Latyshev S, and West C. Determination of illicit drug cutoff values in a pain patient population. Clin Chim Acta 2011; 412:1589-1593.
25. Laffer A, Murphy R, Wingarden W, Pesce A, Mikel C, West C, Egan-City K, Strickland J, Christie J. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Laffer Associates and Millennium Research Institute: Washington D.C., October 2011.